To assess the clinical effectiveness and cost effectiveness of abciximab in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA).
Design-Data from a previous study, the EPIC trial, were used because only this trial was able to provide event data capable of constructing a cost effectiveness analysis over six months.
All other study data reviewed supported the findings of the EPIC trial.
To provide indicative results on long term health outcomes, survival and event-free survival were extrapolated using US epidemiological data in a Markov modelling process.
Setting and patients-Patients who were at high risk for ischaemic complications after PTCA, treated in the standard manner.
Interventions-Abciximab was added to the regimen of intravenous heparin and aspirin.
The EPIC study (n=2099) indicated an 8.1% absolute reduction in serious cardiovascular events (95% confidence interval 3.1% to 12.7%) and a 23% relative risk reduction (p=0.001).
Based on the six month trial period, the additional cost per patient free from a serious event (Australian dollars) is $13 012 and for a special risk/benefit measure of outcome, the additional cost is $14 243.
Epidemiological data support extended survival and ischaemic event-free survival with clinically successful PTCA.
The results of the modelled analysis indicate a cost per additional life-year gained of $5547 and a cost per additional year event-free of $4285. (...)
Mots-clés Pascal : Dilatation instrumentale, Artère coronaire, Resténose, Analyse coût efficacité, Economie santé, Abciximab, Dose unique, Voie intraveineuse, Chimiothérapie, Traitement, Prévention, Complication, Homme, Efficacité traitement, Inhibiteur thromboagrégation, Traitement instrumental
Mots-clés Pascal anglais : Instrumental dilatation, Coronary artery, Restenosis, Cost efficiency analysis, Health economy, Abciximab, Single dose, Intravenous administration, Chemotherapy, Treatment, Prevention, Complication, Human, Treatment efficiency, Antiplatelet agent, Instrumentation therapy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0111178
Code Inist : 002B02G. Création : 22/06/1998.